<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380131</url>
  </required_header>
  <id_info>
    <org_study_id>Alien-Craft 0002</org_study_id>
    <nct_id>NCT02380131</nct_id>
  </id_info>
  <brief_title>Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis</brief_title>
  <official_title>Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stage I：preoperative therapy

        -  Capecitabine plus oxaliplatin with herceptin is superior to surgery alone for patients
           with potentially resectable HER-2 positive gastric cancer with liver metastasis; Stage
           II: Perioperative therapy

        -  Perioperative Capecitabine plus oxaliplatin with herceptin is superior to adjuvant
           Capecitabine plus oxaliplatin alone for patients with potentially resectable HER-2
           positive gastric cancer with liver metastasis;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators assessed whether the addition of a perioperative regimen of XELOX regimen
      with herceptin to improves R0 resection rate and survival among patients with potentially
      resectable HER-2 positive gastric cancer with liver metastasis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival(PFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of Participants with adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HER-2 Positive Gastric Cancer</condition>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Herceptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin plus Capecitabine</intervention_name>
    <description>A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.</description>
    <arm_group_label>Herceptin</arm_group_label>
    <other_name>Oxaliplatin plus capecitabine other names:XELOX.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herceptin</intervention_name>
    <description>Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.</description>
    <arm_group_label>Herceptin</arm_group_label>
    <other_name>Trastuzumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Pathological tissue were gastric cancer by gastric and liver biopsy.

             2.Immunohistochemistry confirmed HER-2 (+)or FISH(+).

             3.gastric cancer with liver metastasis were not able to resectable lesions.

             4.Patients•had not received radiotherapy past and not other organ metastasis and
             peritoneal metastasis.

             5.ECOG performance status 0-1.

             6.Inadequate hematopoietic function： Hemoglobin≥90g/L;
             ANC≥1,500/mm3;Platelet≥100,000/mm3 7.Inadequate organ function which is defined as
             below: Total bilirubin≤1.5 pper limit of normal range (ULN); ALT / AST≤2.5 upper limit
             of normal range (ULN) (≤5.0 x ULN if hepatic metastasis); serum creatinine≤1.5 pper
             limit of normal range (ULN), Serum albumin≥30g/L.

             8.expectancy must be more than 3 months. 9.the random blood or urine pregnancy test in
             fertile woman must be the negative results in pregnancy test in 7 days.

             10.Patients for male and female used reliable contraception contraceptive method until
             the end of study 30 days later.

             11.The operation can complete the D2 operation(LNM≥15).

             12.LVEF≥50%

        Exclusion Criteria:

          -  1. Patients with other extrahepatic metastasis Include peritoneal metastasis.

             3. Patients with other malignancy in 5 years.

             4. Patients with peripheral nerve disease,two hydrogen pyrimidine dehydrogenase( DPD
             )deficiency,upper digestive tract obstruction or from malabsorption syndrome.

             5.Patients with hypertension failed to control, active bleeding, 3~4 proteinuria, heal
             the wound, romboembolism, heart failure, clinical symptoms of heart disease.

             6.Patients have obvious peripheral nervous system disorders,mental disorders and
             disorders of the central nervous system history.

             7.Patients have history of organ transplantation.

             8.Patients with any medical or psychiatric condition or disease which, in the
             investigator's judgment, would make the patient inappropriate for entry into this
             study.

             9.Patients combined antitumor drug outside the research program.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qun Zhao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebei Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine-Oncology</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Zhao, Doctor</last_name>
      <phone>+8613930162111</phone>
      <email>zhaoqun516@126.com</email>
    </contact>
    <investigator>
      <last_name>Qun Zhao, Dortor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>XELOX</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Potentially Resectable Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

